| Outcome Measures: |
Primary: Evaluate the effectiveness of ropinirole and gabapentin on the severity of RLS symptoms in the hemodialysis population., The International Restless Legs Syndrome Study Group (IRLS) rating scale was developed to measure the severity of RLS symptoms over the preceding seven days. The rating scale takes approximately 10 minutes to complete and consists of 10 questions rated from 0 - 4 (0 = none, 4 = very severe). The scale includes diagnostic features and questions to evaluate the intensity/frequency of RLS, associated sleep problems and impact of symptoms on mood and daily functioning. The total score ranges from 0 to 40; mild (1 - 10), moderate (11 - 20), severe (21 - 30) and very severe (31 - 40)., up to 4 & 6 months after start of intervention. | Secondary: Evaluate the impact of ropinirole and gabapentin on the quality of life., The EQ-5D-5L is a two part standardized health status instrument used to measure quality of life over the previous four weeks. The questionnaire contains five, five-point Likert scale (1 = no problems, 5 = extreme problems) questions to evaluate mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The questionnaire also contains a 20 cm vertical visual analogue scale numbered 0 (worst health you can imagine) to 100 (best health you can imagine). This instrument is currently already in use within Alberta Health Services' (AHS) Northern Alberta Renal Program (NARP) for hemodialysis patients., EQ-5D-5L collected at baseline, and 1, 2, 4 & 6 months after start of intervention.|Evaluate the impact of ropinirole and gabapentin on the quality of sleep., The Medical Outcomes Study Sleep Scale (MOS-SS) is used to evaluate six sleep parameter dimensions: sleep initiation, maintenance, respiratory problems quantity, perceived adequacy and somnolence over the past four weeks. Ten of the scale's 12 items are scored using a six-point Likert scale, one uses a five-point Likert scale, and one item is open-ended to record the average amount of hours slept. The scale takes less than five minutes to complete., MOSS-SS collected at baseline, and 1, 2, 4 & 6 months after start of intervention.|Evaluate the impact of ropinirole and gabapentin on the symptom burden., The validated Edmonton Symptom Assessment System Revised Renal (ESAS-r: Renal) consists of 10 visual analogue scales with a superimposed zero to 10 severity scale for pain, activity, nausea, pruritus, depression, anxiety, drowsiness, appetite, well-being, and shortness of breath over the preceding 7 days. The scale for each symptom is anchored by the words 'No' and 'Severe' at zero and 10, respectively. Moderate intensity of any symptom is defined as 4 -6 and severe as 7 - 10 on the Likert scale. A total symptom distress score is calculated by summing of the scores for all 10 symptoms on the ESAS (ranges from 0 to 100)., The 10 item ESAS-r: Renal collected at baseline, and 1, 2, 4 & 6 months after start of intervention.|Validate the addition of RLS and difficulty sleeping items on the Edmonton Symptom Assessment System Revised: Renal (ESAS-r: Renal)., The bi-monthly use of a modified 12 item ESAS-r: Renal has been implemented in to routine clinical care in Alberta Health Services' (AHS) Northern Alberta Renal Program (NARP) to assess patient symptom burden. The assessment used by clinicians includes two additional items scored from 0 to 10: sleep difficulties and restless legs. As a result of the additions, the total symptom distress score ranges from 0-120 for the ESAS version used in the NARP., The restless legs and difficulty sleeping items added to the ESAR-r: renal will be collected at baseline, and 1, 2, 4 & 6 months after start of intervention.
|
| Locations: |
Edmonton General Continuing Care Centre, Edmonton, Canada|Grey Nuns Community Hospital, Edmonton, Canada|Royal Alexandra Hospital, Edmonton, Canada|University of Alberta Hospital, Edmonton, Canada
|
